Sign In
Buy PHAT
$8.23
-0.220 (-2.60%)
At Close: Aug 05, 2026
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
09:35am, Thursday, 30'th Apr 2026
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $1.07 per share a year ago.
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
06:59am, Thursday, 30'th Apr 2026
FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroin
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
08:00am, Monday, 20'th Apr 2026
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analysts
04:25am, Tuesday, 14'th Apr 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat.com rep
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Monday, 06'th Apr 2026
FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroin
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
11:07am, Friday, 27'th Mar 2026
Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.25 Consensus PT from Brokerages
01:47am, Monday, 23'rd Mar 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBeat R
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
06:02pm, Wednesday, 11'th Mar 2026
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
05:09pm, Thursday, 26'th Feb 2026
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates
01:21pm, Thursday, 26'th Feb 2026
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.79 per share a year ago.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
07:00am, Thursday, 26'th Feb 2026
Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 mil
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Monday, 23'rd Feb 2026
FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit
02:05am, Monday, 16'th Feb 2026
Phathom Pharmaceuticals (NASDAQ: PHAT) CEO Steven Basta told attendees at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company's commercial focus over the past year has shifted more he
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
08:00am, Thursday, 05'th Feb 2026
FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
